Eikon Therapeutics logo

Eikon Therapeutics Funding & Investors

Eikon Therapeutics is a biopharmaceutical company employing revolutionary technology at the interface of biology, engineering, and chemistry to discover novel treatments for life-threatening diseases. Eikon’s discovery platform is built on groundbreaking innovations from its founders (Nobel Prize, 2014), culminating in the creation of microscopes that enable real-time, molecular-resolution measurements of protein movement in living cells.

https://eikontx.com/

Total Amount Raised: $772,000,000

Eikon Therapeutics Funding Rounds

  • Series C

    $106,000,000

  • Series B

    $518,000,000

    Series B Investors

    EcoR1 Capital
    Hartford HealthCare Endowment
    Harel Insurance Investments
    Soros Capital Management
    Lux Capital
    The Column Group
    Innovation Endeavors
    StepStone Group
    Schroders Capital
    General Catalyst
    UC Investments
    AME Cloud Ventures
    E15 VC
    CPP Investments
    Foresite Capital
    T. Rowe Price
    Abu Dhabi Investment Authority
    Horizons Ventures
  • Series A

    $148,000,000

    Series A Investors

    Lux Capital
    WPSS.bio
    Foresite Capital
    TCG Crossover
    The Column Group
    Innovation Endeavors
Funding info provided by Diffbot.